midazolam has been researched along with Kidney Failure in 10 studies
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.
midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We herein report a case of dyspnea in an older patient with end-stage heart failure and renal insufficiency successfully controlled with high-dose oxycodone plus midazolam." | 8.31 | [The use of high-dose oxycodone with midazolam for dyspnea due to end-stage heart failure in an older patient with renal insufficiency]. ( Konishi, H; Mano, A; Matsui, H; Nagasawa, Y; Saito, E, 2023) |
| "Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography." | 6.70 | [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002) |
| "We herein report a case of dyspnea in an older patient with end-stage heart failure and renal insufficiency successfully controlled with high-dose oxycodone plus midazolam." | 4.31 | [The use of high-dose oxycodone with midazolam for dyspnea due to end-stage heart failure in an older patient with renal insufficiency]. ( Konishi, H; Mano, A; Matsui, H; Nagasawa, Y; Saito, E, 2023) |
| " In all five patients, the comatose state was immediately reversed by the benzodiazepine-receptor antagonist flumazenil." | 3.69 | Prolonged sedation due to accumulation of conjugated metabolites of midazolam. ( Bauer, TM; Ha, HR; Haberthür, C; Haefeli, WE; Hunkeler, W; Ritz, R; Scollo-Lavizzari, G; Sleight, AJ, 1995) |
| "Midazolam and metabolites were dosed in plasma and ultratiltration liquid by chromatography." | 2.70 | [Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics]. ( Bastien, O; Bolon, M; Boulieu, R; Flamens, C; Lehot, JJ, 2002) |
| "Midazolam is a commonly used sedative in critically ill, mechanically ventilated patients in intensive care unit (ICU) settings worldwide." | 2.44 | Clinical pharmacokinetic monitoring of midazolam in critically ill patients. ( Ensom, MH; Spina, SP, 2007) |
| "Unlike LRT, renal failure derived from long ischemia time was observed in CRT recipients, and it is speculated that renal failure affects the PK of CyA." | 1.35 | Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure. ( Fujimoto, K; Fukushima, K; Ito, Y; Kokuhu, T; Okamoto, M; Sugioka, N; Takada, K; Tanaka, Y; Yoshimura, N, 2009) |
| "Prospective population pharmacokinetic study." | 1.32 | Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients. ( de Hoog, M; de Wildt, SN; van den Anker, JN; van der Giesen, E; Vinks, AA, 2003) |
| "Fluconazole was infused for 30 min at intervals of 24 h, with an initial dose of 400 mg and following doses of 200 mg." | 1.30 | Interaction between fluconazole and midazolam in intensive care patients. ( Ahonen, J; Neuvonen, PJ; Olkkola, KT; Takala, A, 1999) |
| "The effect of renal failure upon the "in vitro" binding of midazolam, a new water-soluble short-acting benzodiazepine, has been studied in man." | 1.28 | The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study. ( Calvo, R; Martínez, I; Rodríguez-Sasiain, JM; Suárez, E, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (30.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Konishi, H | 1 |
| Nagasawa, Y | 1 |
| Matsui, H | 1 |
| Mano, A | 1 |
| Saito, E | 1 |
| Sugioka, N | 1 |
| Fujimoto, K | 1 |
| Tanaka, Y | 1 |
| Fukushima, K | 1 |
| Ito, Y | 1 |
| Kokuhu, T | 1 |
| Okamoto, M | 1 |
| Yoshimura, N | 1 |
| Takada, K | 1 |
| Hoemberg, M | 1 |
| Vierzig, A | 1 |
| Roth, B | 1 |
| Eifinger, F | 1 |
| Bastien, O | 1 |
| Bolon, M | 1 |
| Flamens, C | 1 |
| Lehot, JJ | 1 |
| Boulieu, R | 1 |
| de Wildt, SN | 1 |
| de Hoog, M | 1 |
| Vinks, AA | 1 |
| van der Giesen, E | 1 |
| van den Anker, JN | 1 |
| Spina, SP | 1 |
| Ensom, MH | 1 |
| Belhadj Amor, M | 1 |
| Ouezini, R | 1 |
| Lamine, K | 1 |
| Barakette, M | 1 |
| Labbène, I | 1 |
| Ferjani, M | 1 |
| Bauer, TM | 1 |
| Ritz, R | 1 |
| Haberthür, C | 1 |
| Ha, HR | 1 |
| Hunkeler, W | 1 |
| Sleight, AJ | 1 |
| Scollo-Lavizzari, G | 1 |
| Haefeli, WE | 1 |
| Ahonen, J | 1 |
| Olkkola, KT | 1 |
| Takala, A | 1 |
| Neuvonen, PJ | 1 |
| Calvo, R | 1 |
| Suárez, E | 1 |
| Rodríguez-Sasiain, JM | 1 |
| Martínez, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Active-controlled Study to Compare Efficacy & Safety of Inhaled Isoflurane Delivered by the AnaConDa-S (Anaesthetic Conserving Device) vs IV Midazolam for Sedation in Mechanically Ventilated Paediatric Patients 3-17 Years Old[NCT04684238] | Phase 3 | 97 participants (Actual) | Interventional | 2021-01-14 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for midazolam and Kidney Failure
| Article | Year |
|---|---|
Clinical pharmacokinetic monitoring of midazolam in critically ill patients.
Topics: Critical Care; Drug Monitoring; Humans; Hypnotics and Sedatives; Intensive Care Units; Liver Failure | 2007 |
2 trials available for midazolam and Kidney Failure
| Article | Year |
|---|---|
[Use of midazolam in postoperative sedation of patients with multiple organ failure treated with hemodiafiltration. Clinical study and pharmacokinetics].
Topics: Adjuvants, Anesthesia; Aged; Biotransformation; Chromatography, Liquid; Female; Half-Life; Hemofiltr | 2002 |
[Daily interruption of sedation in intensive care unit patients with renal impairment: remifentanil-midazolam compared to fentanyl-midazolam].
Topics: Anesthetics, Combined; Conscious Sedation; Critical Care; Double-Blind Method; Female; Fentanyl; Hum | 2007 |
7 other studies available for midazolam and Kidney Failure
| Article | Year |
|---|---|
[The use of high-dose oxycodone with midazolam for dyspnea due to end-stage heart failure in an older patient with renal insufficiency].
Topics: Aged, 80 and over; Dyspnea; Female; Heart Failure; Humans; Midazolam; Oxycodone; Renal Insufficiency | 2023 |
Comparison of pharmacokinetics of cyclosporine A in cadaveric and living-related renal transplant recipients and in an experimental rat model of renal failure.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Animals; Area Under Curve; Child; Cycl | 2009 |
Plasma fluoride concentrations during prolonged administration of isoflurane to a pediatric patient requiring renal replacement therapy.
Topics: Anesthetics, Inhalation; Child, Preschool; Conscious Sedation; Fentanyl; Fluorides; Humans; Hypnotic | 2012 |
Population pharmacokinetics and metabolism of midazolam in pediatric intensive care patients.
Topics: Adolescent; Aryl Hydrocarbon Hydroxylases; Bayes Theorem; Child; Child, Preschool; Conscious Sedatio | 2003 |
Prolonged sedation due to accumulation of conjugated metabolites of midazolam.
Topics: Aged; Aged, 80 and over; Animals; Coma; Electroencephalography; Female; Flumazenil; Glucuronates; Hu | 1995 |
Interaction between fluconazole and midazolam in intensive care patients.
Topics: Adult; Analysis of Variance; Antifungal Agents; Critical Care; Cytochrome P-450 CYP3A; Cytochrome P- | 1999 |
The influence of renal failure on the kinetics of intravenous midazolam: an "in vitro" and "in vivo" study.
Topics: Adolescent; Adult; Animals; Blood Proteins; Brain; Disease Models, Animal; Female; Humans; Injection | 1992 |